Analyst Price Targets — ORIC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 3:50 pm | Robert Burns | H.C. Wainwright | $25.00 | $13.27 | TheFly | Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright |
| February 24, 2026 5:34 am | Matthew Biegler | Oppenheimer | $15.00 | $11.71 | StreetInsider | Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC) |
| January 7, 2026 10:19 am | Kelsey Goodwin | Piper Sandler | $22.00 | $8.14 | TheFly | Oric Pharmaceuticals initiated with an Overweight at Piper Sandler |
| December 8, 2025 11:15 am | — | Wells Fargo | $25.00 | $11.00 | TheFly | Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo |
| November 14, 2025 3:58 pm | — | H.C. Wainwright | $23.00 | $12.78 | TheFly | Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright |
| September 4, 2025 9:21 am | Brad Canino | Guggenheim | $18.00 | $10.60 | TheFly | Oric Pharmaceuticals assumed with a Buy at Guggenheim |
| May 6, 2025 11:45 am | Matthew Biegler | Oppenheimer | $12.00 | $5.04 | TheFly | Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer |
| September 5, 2024 4:13 pm | Bradley Canino | Stifel Nicolaus | $20.00 | $9.48 | TheFly | Oric Pharmaceuticals initiated with a Buy at Stifel |
| March 21, 2024 6:32 am | Robert Burns | H.C. Wainwright | $21.00 | $14.59 | StreetInsider | ORIC Pharamceuticals (ORIC) PT Raised to $21 at H.C. Wainwright following 2023 results |
| March 12, 2024 12:55 pm | David Nierengarten | Wedbush | $20.00 | $14.63 | Benzinga | These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results |
Latest News for ORIC
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of…
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES--(BUSINESS WIRE)---- $ORIC--ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). The investigation focuses on ORIC's executive officers and whether investor losses may be recovered under federal securities laws.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ORIC.
U.S. House Trading
No House trades found for ORIC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.